Humacyte (NASDAQ:HUMA) Releases Quarterly Earnings Results, Hits Expectations

Humacyte (NASDAQ:HUMA) posted its quarterly earnings results on Friday. The company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13), FiscalAI reports. The company had revenue of $0.47 million for the quarter, compared to the consensus estimate of $1.35 million.

Here are the key takeaways from Humacyte’s conference call:

• Commercial launch momentum for Symvess — 27 VAC approvals to date, 43 VAC reviews pending, 27 hospitals have ordered (most reordering), and the price cut to $17,000 has raised VAC success to ~70% and increased repeat usage.
• First-of-its-kind U.S. Department of Defense funding has been allocated for procurement and training of biologic vascular repair technologies, which could drive meaningful adoption and non‑commercial volume in 2026.
• Dialysis access is a near-term regulatory catalyst: positive V007 two‑year results support ATEV, the V012 interim analysis (first 80 patients to one year) will report by early June 2026, and Humacyte plans a supplemental BLA submission in H2 2026 if results are supportive.
• Financial mix is mixed — Q4 net loss widened to $24.8M largely due to an $8.9M inventory reserve and unused capacity costs, but FY25 net loss improved to $40.8M year-over-year and liquidity was bolstered by ~$50M cash at year‑end plus subsequent equity raises and a $40M initial tranche of a $77.5M credit facility.
• Pipeline progress beyond trauma — the CTEV coronary graft completed positive preclinical work, an IND was submitted and commercial-scale manufacturing started, targeting first‑in‑human coronary trials in H2 2026.

Humacyte Stock Performance

Shares of HUMA stock opened at $0.68 on Friday. Humacyte has a 12-month low of $0.67 and a 12-month high of $2.93. The business’s fifty day simple moving average is $1.04 and its 200-day simple moving average is $1.28. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97. The company has a market cap of $126.52 million, a PE ratio of -2.94 and a beta of 1.89.

Key Stories Impacting Humacyte

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating and set an outsized $25.00 price target, signaling strong upside expectations from that firm. Benzinga
• Positive Sentiment: Humacyte named Rick McElheny SVP of Business Development to expand collaborations and commercialization efforts—management hire aimed at accelerating partnerships that could drive future revenue. GlobeNewswire: Appointment
• Neutral Sentiment: Full earnings call transcript is available for investors wanting management commentary and Q&A that could clarify outlook and commercial plans. Earnings Call Transcript
• Negative Sentiment: Q4 results: GAAP loss of ($0.13) per share met consensus, but revenue came in at roughly $0.47–0.5M versus analyst expectations near $1.35M (and full‑year sales only $2.0M). The revenue shortfall and low near-term sales reduce near-term visibility and likely pressured the stock. MarketBeat: Earnings Press Release Zacks
• Negative Sentiment: BTIG reduced its price target from $6.00 to $3.00 (still a “buy”), signaling a more cautious near-term outlook from another sell-side firm and lowering consensus upside. Benzinga

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Humacyte by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 7,520,055 shares of the company’s stock valued at $13,085,000 after buying an additional 520,431 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Humacyte by 20.2% during the fourth quarter. Geode Capital Management LLC now owns 3,720,436 shares of the company’s stock worth $3,574,000 after acquiring an additional 624,220 shares during the last quarter. State Street Corp increased its holdings in shares of Humacyte by 17.8% during the fourth quarter. State Street Corp now owns 2,837,276 shares of the company’s stock valued at $2,725,000 after acquiring an additional 429,233 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Humacyte by 5,308.2% during the second quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock valued at $5,516,000 after acquiring an additional 2,590,394 shares in the last quarter. Finally, Millennium Management LLC raised its position in shares of Humacyte by 129.5% in the 4th quarter. Millennium Management LLC now owns 2,631,990 shares of the company’s stock valued at $2,528,000 after purchasing an additional 1,485,152 shares during the last quarter. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the company. Wall Street Zen downgraded Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of Humacyte in a report on Monday, December 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th. Benchmark reduced their price objective on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, January 21st. Finally, D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a report on Friday. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $7.71.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.